Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924446 | 0.87 | RAB9A (0.46) | RAB9ALMNA | |
| SCHEMBL6564201 | 0.80 | ELANE (0.52) | RAB9ALMNA | |
| SCHEMBL6565732 | 0.80 | HSD17B10 (0.47) | RAB9ALMNA | |
| SCHEMBL7866352 | 0.80 | MEN1 (0.50) | TPMTCA1CA2CA9RXRA | |
| SCHEMBL59462 | 0.78 | ELANE (0.48) | — | |
| SCHEMBL9578961 | 0.78 | MAPT (0.50) | CA1CA2CA9RAB9ACA12 | |
| SCHEMBL7871721 | 0.78 | TPMT (0.48) | TPMTCA1CA2CA9RXRA | |
| SCHEMBL1268683 | 0.76 | LDHA (0.47) | CA1CA2CA9RXRARXRB | |
| SCHEMBL3292329 | 0.76 | ALDH1A1 (0.43) | RAB9A | |
| SCHEMBL696908 | 0.76 | KMT2A (0.44) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870706-B2 | Bifunctional cytotoxic agents containing the CTI pharmacophore | PFIZER INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-9598410-B2 | Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-C]pyridines, their use as medicament, and pharmaceutical preparations comprising them | SANOFI (FR) | 2017-03-21 | — | — | US | disclosed |
| WO-2004058754-A1 | BENZOAZOLYPIPERAZINE DERIVATIVES HAVING MGLUR1- AND MGLUR5-ANTAGONISTIC ACTIVITY | EURO-CELTIQUE S.A. (LU) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10870706-B2 | Bifunctional cytotoxic agents containing the CTI pharmacophore | CCNI, TTI1, TTI2 | TPMT 3188/4885CA1 1228/4885CA2 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.